study may be the major reason for smaller infarction size, which might translate to a better long-term prognosis. Expansion of sample size may help to get more persuasive conclusion.
MCCIC, Moscow, Russian Federation
Background: To date, endovascular reperfusion is the essential method for the treatment of AMI, however it has some negative aspects, such as reperfusion injury of the myocardium, distal embolism, etc. Intracoronary administration of drugs provides their fast transport to the target organ and can play a decisive role in the improvement of the results of treatment of AMI. Methods: The study comprised 253 patients (average age -56AE7 years) with acute occlusion of the proximal or middle segment of the LAD and absent antegrade blood flow (TIMI 0), who underwent successful recanalization of IRA within the first 6 hours after the onset of AMI. Prior to angiography, all patients were randomized into 2 groups. Patients from Group I (n¼126) received intracoronary Mexicor (0,2 g). Patients from Group II (control, n¼127) did not receive. Intracoronary administration was performed through a special microcatheter during 10 min. Blood samples for markers of cardiomyocytes injury (Troponin I, myoglobin) were taken during recanalization of IRA, in 12 and 24 hours after the procedure. Results: In-hospital course of the disease was rather uneventful, 1 patient (0,8%) died in Gr. I and 3 (2,3%) -in Gr. II. Average values of Troponin I at 12 hours after the procedure in Grs. I and II were 311AE47 and 632AE39 ng/ml, respectively (p<0,05). In the long-term after the procedure, in average -in 6,8AE0,7 months, the survival in Gr. I was 96,8%, in Gr. 6% (p>0, 05) . Baseline clinical indices in both groups were not significantly different. The increase of LV EF in Grs. I and II was 9,2AE5,1% and 4,1AE8,2%, respectively (p<0,05). We also noted a significantly better dynamics of contractility on infarct-related segments of the LV in Gr.I in comparison with Gr. II (p<0,05) (table 1) . Conclusions: Our study suggests that intracoronary administration of metabolic cytoprotector Mexicor Upoin accordance with a special technique limits reperfusion injury of the myocardium and contributes to the preservation of structural and functional integrity of cardiomyocytes after antegrade blood flow restoration in IRA within the first hours after the onset of AMI.
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Efficacy Background: Rapid time to reperfusion in STEMI is required to maximize myocardial salvage. Conversely, reperfusion success is diminished in patients presenting late. In the randomized MASTER trial, the MGuard Embolic Protection Stent was shown to improve TIMI-3 flow and ST-segment resolution (STR) compared to control DES or BMS. We thus sought to evaluate the impact of symptom onset to balloon time on the efficacy of this novel device. Methods: The MGuard is a novel thin-strut metallic embolic protection stent with a PET micronet covering designed to trap and exclude thrombus and friable atheromatous debris and prevent distal embolization. A total of 433 patients with STEMI <12 hours in duration undergoing PCI were randomized to either the MGuard stent vs. a control (BMS or DES) stent. Results: Symptom onset to balloon time was <180 minutes in 157 pts, and !180 minutes in 253 pts. Pts reperfused early vs. late were more likely to achieve complete STR (58.6% versus 47.0%, P¼0.02), and had more rapid cTFC (15.0 vs. 18.0 frames, p¼0.005). In the entire patient cohort, complete STR and TIMI-3 flow were significantly improved with the MGuard stent compared to control stents (57.8% vs. 44.7%, P¼0.008; and 91.7% vs. 82.9%, p¼0.006, respectively). The results of stent randomization according to symptom onset to balloon time (SBT) appear in the table.
Conclusions: Compared to standard stents, the MGuard Embolic Protection Stent improves reperfusion success in both patients with rapid and delayed time to reperfusion, although the absolute magnitude of benefit may be greater in patients with delays from symptom onset to reperfusion.
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Impact Background: Longer delay from symptom onset to reperfusion has been linked to increased mortality and worse clinical outcome. The mechanism underpinning this association is not entirely clear. Thus, we evaluated the impact of the delay from symptom onset to reperfusion(<3 vs. !3 h) on infarct size and clinical outcomes at 30 days and 1 year in patients with STEMI) treated with primary PCI. Methods: The INFUSE-AMI trial randomized patients with anterior STEMI undergoing primary PCI with bivalirudin anticoagulation to intralesion (IL) bolus abciximab vs. no abciximab, and to thrombus aspiration vs. no aspiration. The primary endpoint was cMRI infarct size (IS, % of left ventricular mass) at 30 days. Time to reperfusion was classified as <3 vs. !3 h. Results: There were 280 (62%) patients with <3h delay and 170 (38%) with !3h delay. Patients with longer delay were significantly older, more often women and diabetics. IS was marginally smaller in patients with shorter delay to reperfusion (16.4% [6.5, 22 .9] vs. 18.1% [10.5, 24.8], respectively, P¼0.07). However, shorter delay to reperfusion was not associated with higher rates of final TIMI 3 flow or myocardial blush grade 2/3. There was significantly lower mortality and morbidity at 30 days and at 1 y in patients with shorter delay (Figure) . Delay !3h was an independent predictor of 1-year MACCE, but not of death or MACE. Conclusions: Even with contemporary primary PCI, longer delay to reperfusion negatively impacts clinical outcome. This effect appears not to be mediated by less successful reperfusion or by a markedly larger infarct size. TUESDAY, OCTOBER 29, 2013, 3:30 PM-5:30 PM presenting with non-ST-segment acute coronary syndromes (NSTEACS) in the largescale ACUITY trial. Methods: ACUITY was as an international randomized trial of different antithrombotic and antiplatelet regimens in 13,819 patients with moderate and high-risk NSTEACS. Revascularization strategy was per discretion of the local clinical team. We compared patients with a history of prior CABG by revascularization strategy (CABG vs. PCI). Results: A total of 1,433 NSTEACS patients with previous CABG underwent revascularization in the ACUITY trial. Of them, 1,360 (94.9%) underwent PCI and 73 (5.1%) underwent redo CABG. Redo CABG was associated with greater rates of postprocedural acute kidney injury (AKI) (30.0% vs. 10.8%, p<0.0001) and 30-day major bleeding (63.1% vs. 6.6%, p<0.0001) compared with PCI. CABG (vs. PCI) was an independent predictor of AKI and major bleeding. At 1-year, redo CABG rather than PCI was associated with higher rates of MI (21.2%% vs. 13.5%, p¼0.04), mortality (13.8% vs. 5.4%, p¼0.0007), and MACE (39.2% vs. 27.8%, p ¼0.007), whereas ischemia-driven target vessel revascularization was more common in the PCI group (12.4% vs. 1.7%, p¼0.02). By multivariable analysis, redo CABG was independently associated with 1-year mortality and MACE (Table) . Conclusions: Patients with prior CABG presenting with NSTEACS who were managed with redo CABG rather than PCI had higher rates of short-and long-term adverse events. While not a randomized trial, these data suggest that PCI should be the favored procedure in the NSTEACS patient with prior CABG in whom revascularization is required. Background: Acute hyperglycemia on admission increases risk of cardiac events after ST-elevated myocardial infarction(STEMI) patients. However, it still remains unclear whether acute glycemic variability has the important prognostic significance. Therefore, this study aimed to evaluate the relationship between cardiac events and the variability of glucose levels by a continuous glucose monitoring system (CGMS).
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Comparison of Revascularization Strategies in Patients with
Methods: This prospective study enrolled 40 patients (age 70AE14 years, 78 % male) with STEMI. All patients were inserted CGMS on admission and were measured at least 48-hours. CGMS provide with glycemic excursion displayed at 5-minutes intervals, 576 points during 48 hours. Primary end points were the incidence of major adverse cardiac events (MACE) at 1 year, including cardiac death, myocardial infarction, and heart failure. Results: We found 3 patterns as the change of glucose wave ( figure) . The three patterns were defined persistent hyperglycemic pattern (PHP), intermittent hyperglycemic pattern (IHP), normal glycemic pattern (NGP). Significant differences were observed regarding the mean amplitude of glycemic excursions among 3 patterns (120AE61mg/dl, 93AE41mg/dl, and 45AE16mg/dl in PHP, IHP, and NGP, respectively p¼0.0004). The MACE incidence rates were 75%, 31%, and 5% in PHP, IHP, and NGP, respectively, (p¼0.17) . 
